MMP9 and neoplasm: For potential testing in in vivo studies, co-occurrence of the antigen on the tumor and sufficient concentration of MMP-9 in the TME would be required, as well as further linker design for endosomal release while avoiding premature proteolytic cleavage of the TAA-binding antibody fragment in serum.